Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Taiho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd. - The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Taiho Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Taiho Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Taiho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Taiho Pharmaceutical Co., Ltd. Snapshot 6 Taiho Pharmaceutical Co., Ltd. Overview 6 Key Facts 6 Taiho Pharmaceutical Co., Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Taiho Pharmaceutical Co., Ltd. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance 18 Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 18 Pre-Registration Products/Combination Treatment Modalities 18 Phase III Products/Combination Treatment Modalities 19 Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 22 IND/CTA Filed Products/Combination Treatment Modalities 22 Preclinical Products/Combination Treatment Modalities 23 Taiho Pharmaceutical Co., Ltd. - Drug Profiles 24 (calcium folinate + gimeracil + oteracil + tegafur) - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 (gimeracil + oteracil + tegafur) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 (tipiracil hydrochloride + trifluridine) - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 bilastine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 netupitant - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 TAS-114 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 TAS-115 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 TAS-116 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 TAS-117 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 TAS-119 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 TAS-120 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 TAS-121 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 TAS-205 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 TAS-303 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 TAS-3681 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 TAS-5567 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 trabectedin - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis 56 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target 56 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 58 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 59 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 60 Taiho Pharmaceutical Co., Ltd. - Dormant Projects 62 Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 63 Discontinued Pipeline Product Profiles 64 (gimeracil + oteracil + tegafur) 64 (tipiracil hydrochloride + trifluridine) 64 orantinib 64 suplatast tosilate 64 Taiho Pharmaceutical Co., Ltd. - Company Statement 65 Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 66 Head Office 66 Other Locations & Subsidiaries 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables Taiho Pharmaceutical Co., Ltd., Key Facts 6 Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9 Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11 Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12 Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13 Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 14 Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 15 Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 16 Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17 Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016 18 Taiho Pharmaceutical Co., Ltd. - Phase III, 2016 19 Taiho Pharmaceutical Co., Ltd. - Phase II, 2016 20 Taiho Pharmaceutical Co., Ltd. - Phase I, 2016 21 Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016 22 Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016 23 Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 57 Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 58 Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 59 Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 61 Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 62 Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 63 Taiho Pharmaceutical Co., Ltd., Subsidiaries 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
